Immunophenotyping predictive of Mycoplasma infection in patients with Chronic Fatigue Syndrome?

Journal of Chronic Fatigue Syndrome

Volumn 11, Issue 2, 2003, Pages 51-69

  Nijs, Jo ^b   Coomans, Danny ^c   Nicolson, Garth L ^a   De Becker, Pascale ^c   Christian, Demanet ^c   De Meirleir, Kenny ^c  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b AZ VUB KRO Gebouw Niveau 1   (Belgium)

^c NONE

Author keywords

Chronic fatigue syndrome; Immunity; Immunofluorescence; Mycoplasma

Indexed keywords

CD5 ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ADULT; ARTICLE; B LYMPHOCYTE; BACTERIAL INFECTION; BLOOD VESSEL; CELL ACTIVATION; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE SYSTEM; IMMUNOFLUORESCENCE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MYCOPLASMA HOMINIS; MYCOPLASMA PENETRANS; MYCOPLASMA PNEUMONIAE; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PHENOTYPE;

EID: 0042521095     PISSN: 10573321     EISSN: None     Source Type: Journal    
DOI: 10.1300/J092v11n02_05     Document Type: Article

References (32)

1. Fukuda K, Strauss SE, Hickie I, et al. The Chronic Fatigue Syndrome, a comprehensive approach to its definition and study. Ann Intern Med 1994; 121:953-959.
2. Rawadi G. Mycoplasma fermentans interaction with monocytes/macrophages: molecular basis. Microbes Infect 2000; 2:955-964.
3. Nasralla M, Haier J, Nicolson GL. Multiple mycoplasmal infections detected in blood of patients with Chronic Fatigue Syndrome and/or Fibromyalgia. Eur J Clin Microbiol Infect Dis 1999; 18:859-865.
4. Vojdani A, Choppa PC, Tagle C, Andrin R, Samimi B, Lapp CW. Detection of Mycoplasma genus and Mycoplasma fermentans by PCR in patients with Chronic Fatigue Syndrome. FEMS Immunol Med Microbiol 1998; 22:355-365.
5. Nasralla MY, Haier J, Nicolson NL, Nicolson GL. Examination of mycoplasmas in blood of 565 chronic illness patients by polymerase chain reaction. In J Med Biol Environ 2000; 28:15-23.
6. Nicolson GL, Nasralla MY, Franco AR, et al. Role of mycoplasmal infections in fatigue illnesses: Chronic Fatigue and Fibromylagia Syndromes, Gulf War Illness and Rheumatoid Arthritis. JCFS 2000; 6:23-39.
7. Nicolson GL, Nasralla M, Haier J, Nicolson NL. Diagnosis and treatment of chronic mycoplasmal infections in fibromylagia and chronic fatigue syndromes: relationship to gulf war illness. Biomed Ther 1998; 16:266-271.
8. Nicolson GL, Nicolson NL. Diagnosis and treatment of mycoplasmal infections in Persian Gulf War Illness-CFIDS patients. Int J Occupat Med Immunol Toxicol 1996; 5:67-78.
9. Suhadolnik RJ, Reichenbach NL, Hitzges P, et al. Upregulation of the 2-5A synthetase/Rnase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994; 18:S96-S104.
10. De Meirleir K, Bisbal C, Campine I, et al. A 37 kDa 2-5A binding protein as a potential biochemical marker for Chronic Fatigue Syndrome. Am J Med 2000; 108: 99-105.
11. Suhadolnik RJ, Peterson DL, O'Brien K, et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res 1997; 17:377-385.
12. Baseman JB, Tully JG. Mycoplasmas: sophisticated, re-emerging and burdened by their notoriety. Emerg Infect Dis 1997; 3:21-23.
13. Zhang Q, Zhou X-D, Denny T, et al. Changes in immune parameters seen in gulf war veterans but not in civilians with Chronic Fatigue Syndrome. Clin Diagn Lab Immunol 1999; 6:6-13.
14. Levine PH, Whiteside TL, Friberg D, Bryant J, Colclough G, Herbertman RB. Dysfunction of natural killer cell activity in a family with chronic fatigue syndrome. Clin Immunol Immunopathol 1998; 88:99-104.
15. Whiteside TL, Friberg D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med 1998; 105:27S-34S.
16. Baum SC. Mycoplasma diseases. In: Principles and practice of infectious diseases (Mandell, G.L., Bennett, J.E., Dolin, R., Eds.) 1995; pp. 1701-1712. Churchill Livingstone, New York.
17. Kikkawa S, Matsumoto M, Sasaki T, et al. Complement activation in Mycoplasma fermentans-induced Mycoplasma clearence from infected cells: probing of the organism with monoclonal antibodies against M161Ag. Infect Immun 2000; 68:1672-1680.
18. Nishiguchi M, Matsumoto M, Takao T, et al. Mycoplasma fermentans lipoprotein M161Ag-induced cell activation is mediated by toll-like receptor 2: role of N-terminal hydrophobic portion in its multiple functions. J Immunol 2001; 166:2610-2616.
19. Matsumoto M, Seya T. M161Ag is a potent cytokine inducer with complement activating function. Int J Mol Med 1999; 3:291-295.
20. Cartner SC, Lindsey JR, Gibbs-Erwin J, Cassell GH, Simecka JW. Roles of innate and adaptive immunity in respiratory Mycoplasmosis. Infect Immun 1998; 66: 3485-3491.
21. Romero-Rojas A, Ponce-Hemandez C, Mendoza SE, Reyes-Esparza JA, Estrada-Parra S, Hadden JW. Immunomodulatory properties of Mycoplasma pulmonis. II Studies on the mechanisms of immunomodulation. Int Immunopharmacol 2001; 1: 1689-1697.
22. Brieman L, Friedman JH, Ohlsen R, Stone CJ. Classification and Regression Trees. Belmont California: Wadsworth International Group. 1984.
23. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic Fatigue Syndrome, a working case definition. Ann Intern Med 1988; 108:387-389.
24. Levy JA. Viral studies of Chronic Fatigue Syndrome. Clin Infect Dis 1994; 18:S117-S120.
25. Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA. Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis 1994; 18:S136-S141.
26. Hassan IS, Bannister BA, Akbar A, Weir W, Bofill M. A study of the immunology of the chronic fatigue syndrome: correlation of immunologic parameters to health dysfunction. Clin Immunol Immunopathol 1998; 87:60-67.
27. Peakman M, Deale A, Field R, Mahalingham M, Wessely S. Clinical improvement in chronic fatigue syndrome is not associated with lymphocyte subsets or function or activation. Clin Immunol Immunopathol 1997; 82:83-91.
28. Swanink CM, Vercoulen JH, Galama JM, Roos MT, Meyaard L, van der Ven-Jongekrijg J, de Nijs R, Bleijenberg G, Fennis JF, Miedema F, van der Meer JW. Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome. J Infect Dis 1996; 173:460-463.
29. Roitt I, Brostoff J, Male D. Cells involved in the immune response. In: Immunology: Fifth edition. (Roitt, I., Brostoff, J., Male, D., Eds.), 1998; p. 19. Mosby, London.
30. Tirelli U, Marotta G, Improta S, Pinto A. Immunological abnormalities in patients with Chronic Fatigue Syndrome. Scand J Immunol 1994; 40:601-608.
31. Klimas N, Salvato F, Morgan R, Fletcher MA. Immunologic abnormailities in chronic fatigue syndrome. J Clin Microbiol 1990; 28:1403-1410.
32. Landay AL, Jessop C, Lennette ET, Levy JA. Chronic Fatigue Syndrome: clinical condition associated with immune activation. Lancet 1991; 338:707-712.